Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Cardiovascular
Immunology
Neuroscience
Oncology
ScemblixⓇ - BCR-ABL inhibitor
NCT04971226 ASC4FIRST (CABL001J12301)
Indication
Chronic myeloid leukemia, 1st line
Phase 3
Major Molecular Response (MMR) at week 48
Phase
Patients
402
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Arm 1: asciminib 80 mg QD
Arm 2: Investigator selected TKI including one of the below treatments:
-Imatinib 400 mg QD
- Nilotinib 300 mg BID
- Dasatinib 100 mg QD
Bosutinib 400 mg QD
Patients with newly diagnosed philadelphia chromosome positive chronic
myelogenous leukemia in chronic phase
Read-out
Milestone(s)
2024
Publication
TBD
79 Investor Relations | Q3 2022 Results
References
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation